Keyphrases
Neurofibromatosis Type I
100%
Neurofibromatosis Type 1 (NF-1)
100%
Treatment Decisions
100%
MEK Inhibitor (MEKi)
100%
Plexiform Neurofibroma
100%
Pediatric Patients
20%
Medical Therapy
20%
Medical Treatment
20%
Selumetinib
20%
Treatment Options
10%
Tumor
10%
Targeted Therapy
10%
Improved Outcomes
10%
Tumor Volume
10%
Treatment Strategy
10%
Tyrosine Kinase Inhibitor
10%
Negative Regulator
10%
Phase II Trial
10%
Surgical Resection
10%
Complex Disease
10%
Range of Motion
10%
Gene Variants
10%
Cabozantinib
10%
Neurofibromin
10%
Multidisciplinary Team
10%
Heterogeneous Disease
10%
MEK1
10%
Binimetinib
10%
Clinical Decision-making
10%
Tumor Predisposition Syndrome
10%
Patient-reported Outcomes
10%
Quality of Life Improvement
10%
Patient Preference
10%
Single Treatment
10%
Trametinib
10%
Multiple Aspects
10%
Peripheral Nerve Sheath Tumor
10%
Watchful Waiting
10%
Morbidity Outcome
10%
Family Decision
10%
Treatment Pathways
10%
Medicine and Dentistry
Neurofibromatosis Type I
100%
MEK Inhibitor
100%
Plexiform Neurofibroma
100%
Combination Therapy
40%
Neoplasm
30%
Pediatrics Patient
20%
Selumetinib
20%
Diseases
20%
Targeted Therapy
10%
Disease Predisposition
10%
Clinician
10%
Clinical Study
10%
Quality of Life
10%
Patient-Reported Outcome
10%
Cabozantinib
10%
Clinical Decision Making
10%
Range of Motion
10%
Trametinib
10%
Tyrosine-Kinase Inhibitor
10%
Nerve Sheath Tumor
10%
Watchful Waiting
10%
Binimetinib
10%
Peripheral Nerve
10%
Surgery
10%